Euro-Excellence Inc v Kraft Canada Inc

EARLY WARNING NEWS RELEASE

Retrieved on:

Thursday, October 19, 2023

TORONTO, ON, Oct. 18, 2023 (GLOBE NEWSWIRE) --

Key Points:

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES
This news release is being issued by 15384150 Canada Inc. (the “Purchaser”) as required by National Instrument 62-103 – The Early Warning System and Related Take-Over Bid and Insider Reporting Issues in connection with its potential acquisition and disposition of certain securities in the capital of BBTV Holdings Inc. (the "Company").
To obtain copies of the early warning report, please contact James Szumski at Owens Wright LLP (416-848-4706, [email protected]).
Please refer to the Company’s press release dated October 17, 2023 for additional details on the Transaction.
An early warning report will be filed by the Purchaser, on its own behalf and on behalf of those parties acting jointly or in concert with it, under applicable securities laws and will be available on the Company’s profile on SEDAR+ at www.sedarplus.ca .

Flowserve intends to terminate the Arrangement Agreement as Regulatory Approval from France will not be obtained

Retrieved on:

Thursday, October 5, 2023

Euro-Excellence Inc v Kraft Canada Inc, TSX, VLN, Regulation, Arrangement, Sale, Lease, Flowserve, Velan

As previously disclosed, the conclusion of the transactions set out in the Arrangement Agreement was conditional on the Regulatory Approvals, including one from France.

Key Points:

As previously disclosed, the conclusion of the transactions set out in the Arrangement Agreement was conditional on the Regulatory Approvals, including one from France.
In order to meet that key condition, Flowserve offered a package of remedies and undertakings to the French Authorities.
Flowserve has consequently informed Velan of its intention to terminate the Arrangement Agreement following the Outside Date.
Velan will resume operations as an independent business, free of the covenants and other restrictions of the Arrangement Agreement.

BELLUS Health Inc. Announces Voting Results from Special Meeting of Shareholders

Retrieved on:

Friday, June 16, 2023

89,309,640 votes, or 99.99% of the votes cast at the Special Meeting by Shareholders present or represented by proxy were cast in favour of the special resolution approving the Arrangement (the “Arrangement Resolution”) (82,218,148 votes, or 99.99% of the votes cast in favour of the Arrangement Resolution, excluding Shares required to be excluded pursuant to Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions).

Key Points:

89,309,640 votes, or 99.99% of the votes cast at the Special Meeting by Shareholders present or represented by proxy were cast in favour of the special resolution approving the Arrangement (the “Arrangement Resolution”) (82,218,148 votes, or 99.99% of the votes cast in favour of the Arrangement Resolution, excluding Shares required to be excluded pursuant to Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions).
The Arrangement Resolution was required to be passed by (i) at least two-thirds of the votes cast at the Special Meeting by the Shareholders present or represented by proxy and entitled to vote at the Special Meeting; and (ii) a simple majority of the votes cast at the Special Meeting by the Shareholders present or represented by proxy and entitled to vote at the Special Meeting, excluding for this purpose any person required to be excluded pursuant to Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions.
Details of the voting results will be filed under the Company’s profile on the SEC website at www.sec.gov and on SEDAR at www.sedar.com .
BELLUS will present its application for a final order to the Superior Court of Québec (the “Court”) on June 22, 2023.

Velan Shareholders Approve Acquisition by Flowserve

Retrieved on:

Friday, May 5, 2023

Minority, VLN, SVS, Shareholder, Superior court, Sale and purchase of ship, MVS, Arrangement, Meeting, Euro-Excellence Inc v Kraft Canada Inc, Flowserve, SEDAR, Court, TSX, Multilateral, Proxy, Security (finance), Velan

At the Meeting, Velan Shareholders carrying an aggregate of 82,540,128 votes, representing approximately 98.44% of votes entitled to be cast at the Meeting, were represented virtually or by proxy at the Meeting.

Key Points:

At the Meeting, Velan Shareholders carrying an aggregate of 82,540,128 votes, representing approximately 98.44% of votes entitled to be cast at the Meeting, were represented virtually or by proxy at the Meeting.
The Arrangement remains subject to the approval of the Superior Court of Québec and the satisfaction or waiver of other customary closing conditions, including the regulatory approvals and clearances.
The Court hearing for the final order to approve the Arrangement is expected to take place on May 16, 2023 and the completion of the Arrangement is now expected to occur in the third quarter of 2023 (calendar year).
Further information regarding the Arrangement can be found in the management information circular filed by Velan on April 4, 2023, which is available at https://www.velan.com/en/company/investor_relations and under Velan’s profile on SEDAR at www.sedar.com .

Braxia Scientific Announces Voting Results from the Annual General and Special Meeting of Shareholders

Retrieved on:

Tuesday, November 1, 2022

For more details on the matters covered at the annual meeting, please refer to the Company's management information circular available on SEDAR at www.sedar.com .Final voting results on all matters voted on at the annual meeting will also be filed on SEDAR.

Key Points:

For more details on the matters covered at the annual meeting, please refer to the Company's management information circular available on SEDAR at www.sedar.com .Final voting results on all matters voted on at the annual meeting will also be filed on SEDAR.
Braxia Scientific is a medical research company with clinics that provide innovative ketamine treatments for persons with depression and related disorders.
Through its medical solutions, Braxia aims to reduce the illness burden of brain-based mental disorders such as major depressive disorder among others.
Braxia seeks to develop ketamine and derivatives and other psychedelic products from its IP development platform.

KetaMD Expands Access to Breakthrough Ketamine Therapy in Florida to Battle the Growing Mental Health Crisis and Shortage of Mental Health Care Providers

Retrieved on:

Tuesday, October 4, 2022

Post-traumatic stress disorder, OTC, National Alliance on Mental Illness, Anxiety, News, Tropical Storm Ian, Telehealth, Lists of diseases, Euro-Excellence Inc v Kraft Canada Inc, National Alliance, Psychiatry, National Helping Families in Mental Health Crisis Day, National Suicide Prevention Week, Psilocybin, CEO, Ketamine, Population, CSE, Multimedia, Disorder, COVID-19, Mental disorder, Risk, Awareness, Growth, CDSA, The Journal of Clinical Psychiatry, Clifford Whittingham Beers, Rapids, Quality of life, Controlled Drugs and Substances Act, Journal, Suicidal ideation, Patient, Person, Drug prohibition law, Diagnosis, Removal of cannabis from Schedule I of the Controlled Substances Act, Forward-looking statement, Intention, Mental health, Depression, Company, Mental Illness Awareness Week, Pharmaceutical industry, Medicine, Audit

KetaMD is committed to battling the growing mental health crisis and alleviating the growing shortage of mental health care providers in Florida and across America, both issues further exacerbated by the COVID-19 pandemic.

Key Points:

KetaMD is committed to battling the growing mental health crisis and alleviating the growing shortage of mental health care providers in Florida and across America, both issues further exacerbated by the COVID-19 pandemic.
Mental Health Crisis by the Numbers:
1 in 5 U.S. adults experience mental illness each year.
Over 6.3 million people in Florida live in a community that does not have enough mental health professionals.
Florida ranks 49th in the nation for access to mental health care, according to Mental Health America.

CSE Bulletin: Notice of Distribution and Delist - Arctic Glacier Income Fund (AG.UN)

Retrieved on:

Friday, September 30, 2022

Transfer, Arctic Glacier, Mutual fund, Ecological Monitoring Centre, Senegal, Intention, Stock, Euro-Excellence Inc v Kraft Canada Inc, Plan, CAD, Court, Pension fund, Viticulture, Fund

Toronto, Ontario--(Newsfile Corp. - Le 30 septembre/September2022) - Arctic Glacier Income Fund (the Fund) has announced its intention to make a final distribution to unitholders of the Fund, terminate the Fund and delist the units.

Key Points:

Toronto, Ontario--(Newsfile Corp. - Le 30 septembre/September2022) - Arctic Glacier Income Fund (the Fund) has announced its intention to make a final distribution to unitholders of the Fund, terminate the Fund and delist the units.
The Final Distribution will be made pursuant to the Plan of Compromise or Arrangement of, inter alia, the Fund dated May 21, 2014, as amended (the Plan).
Arctic Glacier Income Fund ( Fund ) a annonc son intention d'effectuer une distribution finale aux porteurs de parts du Fund, de dissoudre le Fund et de radier les parts de la cote.
La distribution finale sera effectue conformment au plan de compromis ou d'arrangement, entre autres, du Fund dat du 21 mai 2014, tel que modifi (le plan ).

Braxia Scientific Announces Board Appointment

Retrieved on:

Thursday, September 22, 2022

TORONTO, Sept. 21, 2022 /PRNewswire/ - Braxia Scientific Corp. ("Braxia Scientific", or the "Company"), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960) a medical research and telemedicine company with clinics providing innovative ketamine and psilocybin treatments for depression and related disorders, is pleased to announce that Leann Taylor, President and COO of KetaMD, Inc. ("KetaMD"), has joined the board of directors.

Key Points:

TORONTO, Sept. 21, 2022 /PRNewswire/ - Braxia Scientific Corp. ("Braxia Scientific", or the "Company"), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960) a medical research and telemedicine company with clinics providing innovative ketamine and psilocybin treatments for depression and related disorders, is pleased to announce that Leann Taylor, President and COO of KetaMD, Inc. ("KetaMD"), has joined the board of directors.
KetaMD, a telemedicine platform recently acquired by Braxia Scientific, provides access to at-home ketamine treatments for people suffering from mental health disorders such as depression, bipolar disorder, anxiety and post-traumatic stress disorder (PTSD).
Braxia Scientific is a medical research and telemedicine company with clinics that provide innovative ketamine treatments for persons with depression and related disorders.
Through its medical solutions, Braxia aims to reduce the illness burden of brain-based disorders, such as major depressive disorder among others.

Braxia Scientific Announces Court Approval of Class Action Settlement in Canada

Retrieved on:

Saturday, September 17, 2022

TORONTO, Sept. 16, 2022 /PRNewswire/ - Braxia Scientific Corp. ("Braxia Scientific", or the "Company"), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960) announced today that the Supreme Court of British Columbia has approved a settlement of a class action lawsuit that was filed in May 2021 against Braxia Scientific, its CEO, certain of its former officers, a shareholder, and underwriters (the "Canadian Settlement").

Key Points:

TORONTO, Sept. 16, 2022 /PRNewswire/ - Braxia Scientific Corp. ("Braxia Scientific", or the "Company"), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960) announced today that the Supreme Court of British Columbia has approved a settlement of a class action lawsuit that was filed in May 2021 against Braxia Scientific, its CEO, certain of its former officers, a shareholder, and underwriters (the "Canadian Settlement").
The court approval of an agreement in principle (the "US Settlement") to settle claims alleged in a securities class action (the "US Class Action") against the Company and certain of its former officers filed in the United States District Court for the Central District of California in April, 2021, remains pending.
The US Settlement contemplates a cash payment by the Company of USD $1 million to settle the US Class Action.
After available insurance, and assuming the court approval of the US Settlement is obtained, the total cost to the Company to settle both class actions will be approximately CDN $1.36million.

Braxia Scientific Launches KetaMD in Florida; First Patients Complete Initial Virtual Ketamine Treatments At-Home

Retrieved on:

Monday, September 12, 2022

KetaMD onboarded new patients and completed initial ketamine treatments.

Key Points:

KetaMD onboarded new patients and completed initial ketamine treatments.
Dr. Roger McIntyre commented, "We are incredibly proud to have treated our first patients in the U.S. through our KetaMD platform.
KetaMD is a HIPAA-compliant telemedicine platform providing affordable and potentially life-changing at-home medical ketamine treatments.
Braxia Scientific is a medical research and telemedicine company with clinics that provide innovative ketamine and psilocybin treatments for people with depression and related disorders.